CN Patent

CN103391771A — 包含二甲双胍和dpp-4抑制剂或sglt-2抑制剂的药物组合物

Assigned to Boehringer Ingelheim International GmbH · Expires 2013-11-13 · 13y expired

What this patent protects

本发明涉及包含DPP-4抑制剂药物和/或SGLT-2抑制剂药物和二甲双胍XR的固定剂量复方制剂的药物组合物，其制备方法，和其治疗具体疾病的用途。

USPTO Abstract

本发明涉及包含DPP-4抑制剂药物和/或SGLT-2抑制剂药物和二甲双胍XR的固定剂量复方制剂的药物组合物，其制备方法，和其治疗具体疾病的用途。

Drugs covered by this patent

Jardiance (empagliflozin) · Boehringer Ingelheim

Patent Metadata

Patent number: CN103391771A
Jurisdiction: CN
Classification: —
Expires: 2013-11-13
Drug substance claim: No
Drug product claim: No
Assignee: Boehringer Ingelheim International GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.